From: The inclusion of real world evidence in clinical development planning
 | Placebo | Nataluzimab | Fingolimod 1.25 | Fingolimod 0.5 | Avonex | Rebif 22 | Rebif 44 | Copaxone | Betaferon |
---|---|---|---|---|---|---|---|---|---|
Placebo | Â | 0.314 (0.03) | 0.462 (0.03) | 0.423 (0.03) | 0.832 (0.06) | 0.727 (0.07) | 0.679 (0.05) | 0.659 (0.04) | 0.670 (0.05) |
Nataluzimab | 0.407 (0.07) | Â | 1.488 (0.20) | 1.361 (0.20) | 2.677 (0.30) | 2.336 (0.30) | 2.183 (0.30) | 2.120 (0.30) | 2.157 (0.3) |
Fingolimod 1.25 | 0.455 (0.05) | 1.150 (0.23) | Â | 0.918 (0.08) | 1.808 (0.17) | 1.581 (0.19) | 1.476 (0.15) | 1.433(0.14) | 1.458 (0.15) |
Fingolimod 0.5 | 0.413 (0.05) | 1.045 (0.22) | 0.916 (0.12) | Â | 1.977 (0.19) | 1.728 (0.21) | 1.614 (0.17 | 1.567 (0.16) | 1.594 (0.17) |
Avonex | 0.783 (0.07) | 1.977 (0.36) | 1.742 (0.24) | 1.920 (0.27) | Â | 0.877 (0.09) | 0.818 (0.06) | 0.795 (0.07) | 0.808 (0.07) |
Rebif 22 | 0.766 (0.08) | 1.933 (0.36) | 1.706 (0.26) | 1.880 (0.30) | 0.982 (0.10) | Â | 0.939 (0.08) | 0.913 (0.10) | 0.929 (0.10) |
Rebif 44 | 0.7482 (0.08) | 1.887 (0.35) | 1.666 (0.26) | 1.837 (0.30) | 0.959 (0.10) | 0.983 (0.11) | Â | 0.974 (0.07) | 0.991 (0.09 |
Copaxone | 0.601 (0.05) | 1.517 (0.28) | 1.338 (0.19) | 1.474 (0.21) | 0.771 (0.07) | 0.790 (0.09) | 0.809 (0.09) | Â | 1.019 (0.07) |
Betaferon | 0.700 (0.07) | 1.768 (0.32) | 1.559 (0.22) | 1.718 (0.25) | 0.897 (0.07) | 0.920 (0.09) | 0.943 (0.1) | 1.170 (0.11) | Â |